Time-restricted Eating and High-intensity Interval Training After Gestational Diabetes (TRE-HIITmoms)
17. august 2026 opdateret af: Norwegian University of Science and Technology
Time-restricted Eating and High-intensity Interval Training After Gestational Diabetes (TRE-HIIT Moms)
This trial will recruit participants who had gestational diabetes in their most previous pregnancy.
Participants will be randomly allocated into two groups: one intervention group and one control group 6-12 weeks after giving birth.
The intervention group will undergo an 8-week supervised intervention consisting of time-restricted eating and endurance exercise training with moderate-to-high intensity.
The investigators will assess cardiorespiratory fitness, body composition, and other markers of cardiovascular and metabolic health before and after the 8 weeks.
Additionally, the participants in the intervention group will be encouraged to continue exercising and eating time restricted after the supervised period and follow them up by telephone until one year from the baseline visit.
The investigators will measure the same outcomes at the follow-up as on the previous two test points.
Studieoversigt
Status
Ikke rekrutterer endnu
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
TREHIIT Moms is a randomised, controlled trial with two parallel groups. To be eligible for the trial, the participants need to have had gestational diabetes in their most previous pregnancy and be 6-12 weeks postpartum at inclusion. Participants will be randomly allocated to intervention or control (1:1). The intervention consist of time-restricted eating and endurance exercise. Time-restricted eating implies restricting energy intake to a maximum 10-hour time window daily. The exercise training will be supervised and consist of 2-4 weekly sessions of moderate-to-high intensity exercise. After the supervised period, the participants will continue high-intensity exercise and time-restricted eating at home, with follow-up from the researchers until 1 year from baseline.
The investigators will assess cardiometabolic health outcomes and psychological well-being at baseline, after 8 weeks, and 1 year. Human milk samples will be collected at baseline and 8 weeks and stored for future exploratory analyses of milk composition. The specific analytes and analytical methods will be determined in subsequent exploratory studies and are not prespecified trial outcomes
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
56
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Trine Moholdt, PhD
- Telefonnummer: +4797098594
- E-mail: trine.moholdt@ntnu.no
Undersøgelse Kontakt Backup
- Navn: Beathe Sitter, PhD
- Telefonnummer: +4799024180
- E-mail: beathe.sitter@ntnu.no
Studiesteder
-
-
-
Trondheim, Norge, 7491
- Department of Circulation and Medical Imaging
-
Ledende efterforsker:
- Trine Moholdt, PhD
-
Kontakt:
- Trine Moholdt, PhD
- Telefonnummer: +4797098594
- E-mail: trine.moholdt@ntnu.no
-
Kontakt:
- Beathe Sitter, PhD
- Telefonnummer: +4799024180
- E-mail: beathe.sitter@ntnu.no
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
Tager imod sunde frivillige
Ingen
Beskrivelse
Inclusion Criteria:
- Gestational diabetes mellitus in most recent pregnancy
- Within 6-12 weeks postpartum
- Understands oral and written Norwegian or English
- Able to walk or run on a treadmill or ride a bike for at least 60 minutes
- Living in the Trondheim area
Exclusion Criteria:
- Pregnant or trying to become pregnant
- Diagnosed with type 1 or type 2 diabetes
- Diagnosed with cardiovascular disease
- Have a history of eating disorders (anorexia, bulimia, or binge eating disorder)
- Habitual eating window of less than 12 hours/day
- Engaging in regular high-intensity endurance training (once per week or more)
- Intention of starting an exercise programme and/or a dietary strategy within the study period
- Shift work that includes night shifts
- Bariatric surgery
- Any other reason which, according to the researchers, makes the potential participant ineligible
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Intervention
Time-restricted eating and high-intensity interval training
|
The intervention is a combination of time-restricted eating and endurance exercise training.
Time-restricted eating implies that the participants will be asked to limit their energy intake to a maximum 10-hour time window daily.
The endurance exercise programme consists of 2-4 weekly supervised exercise sessions for 8 weeks.
Thereafter, the participants will continue exercising unsupervised with weekly follow-up from researchers.
Andre navne:
|
|
Ingen indgriben: Control
No intervention administered
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Peak oxygen uptake
Tidsramme: From baseline to after 8 weeks
|
Direct measurement of oxygen uptake during graded maximal exercise test to exhaustion
|
From baseline to after 8 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Peak oxygen uptake
Tidsramme: From baseline to after 12 months
|
Direct measurement of oxygen uptake during graded maximal exercise test to exhaustion
|
From baseline to after 12 months
|
|
Body mass
Tidsramme: From baseline to after 8 weeks
|
Estimated by bioimpedance scale
|
From baseline to after 8 weeks
|
|
Body mass
Tidsramme: From baseline to after 12 months
|
Estimated by bioimpedance scale
|
From baseline to after 12 months
|
|
Fat mass
Tidsramme: From baseline to after 8 weeks
|
Estimated by bioimpedance scale
|
From baseline to after 8 weeks
|
|
Fat mass
Tidsramme: From baseline to after 12 months
|
Estimated by bioimpedance scale
|
From baseline to after 12 months
|
|
Muscle mass
Tidsramme: From baseline to after 8 weeks
|
Estimated by bioimpedance scale
|
From baseline to after 8 weeks
|
|
Muscle mass
Tidsramme: From baseline to after 12 months
|
Estimated by bioimpedance scale
|
From baseline to after 12 months
|
|
Visceral fat area
Tidsramme: From baseline to after 8 weeks
|
Estimated by bioimpedance scale
|
From baseline to after 8 weeks
|
|
Visceral fat area
Tidsramme: From baseline to after 12 months
|
Estimated by bioimpedance scale
|
From baseline to after 12 months
|
|
Bone mass
Tidsramme: From baseline to after 8 weeks
|
Estimated by bioimpedance scale
|
From baseline to after 8 weeks
|
|
Bone mass
Tidsramme: From baseline to after 12 months
|
Estimated by bioimpedance scale
|
From baseline to after 12 months
|
|
Waist circumference
Tidsramme: From baseline to after 8 weeks
|
Measured by measuring tape at the level of the umbilicus
|
From baseline to after 8 weeks
|
|
Waist circumference
Tidsramme: From baseline to after 12 months
|
Measured by measuring tape at the level of the umbilicus
|
From baseline to after 12 months
|
|
Systolic blood pressure
Tidsramme: From baseline to after 8 weeks
|
Measured by automatic blood pressure cuff
|
From baseline to after 8 weeks
|
|
Systolic blood pressure
Tidsramme: From baseline to after 12 months
|
Measured by automatic blood pressure cuff
|
From baseline to after 12 months
|
|
Diastolic blood pressure
Tidsramme: From baseline to after 8 weeks
|
Measured by automatic blood pressure cuff
|
From baseline to after 8 weeks
|
|
Diastolic blood pressure
Tidsramme: From baseline to after 12 months
|
Measured by automatic blood pressure cuff
|
From baseline to after 12 months
|
|
Resting heart rate
Tidsramme: From baseline to after 8 weeks
|
Measured by automatic blood pressure cuff
|
From baseline to after 8 weeks
|
|
Resting heart rate
Tidsramme: From baseline to after 12 months
|
Measured by automatic blood pressure cuff
|
From baseline to after 12 months
|
|
Blood cholesterol
Tidsramme: From baseline to after 8 weeks
|
Venous blood sampling
|
From baseline to after 8 weeks
|
|
Blood cholesterol
Tidsramme: From baseline to after 12 months
|
Venous blood sampling
|
From baseline to after 12 months
|
|
LDL cholesterol
Tidsramme: From baseline to after 8 weeks
|
Venous blood sampling
|
From baseline to after 8 weeks
|
|
LDL cholesterol
Tidsramme: From baseline to after 12 months
|
Venous blood sampling
|
From baseline to after 12 months
|
|
HDL cholesterol
Tidsramme: From baseline to after 8 weeks
|
Venous blood sampling
|
From baseline to after 8 weeks
|
|
HDL cholesterol
Tidsramme: From baseline to after 12 months
|
Venous blood sampling
|
From baseline to after 12 months
|
|
Triglycerides
Tidsramme: From baseline to after 8 weeks
|
Venous blood sampling
|
From baseline to after 8 weeks
|
|
Triglycerides
Tidsramme: From baseline to after 12 months
|
Venous blood sampling
|
From baseline to after 12 months
|
|
Fasting glucose
Tidsramme: From baseline to after 8 weeks
|
Venous blood sampling
|
From baseline to after 8 weeks
|
|
Fasting glucose
Tidsramme: From baseline to after 12 months
|
Venous blood sampling
|
From baseline to after 12 months
|
|
Insulin C-peptide
Tidsramme: From baseline to after 8 weeks
|
Venous blood sampling
|
From baseline to after 8 weeks
|
|
Insulin C-peptide
Tidsramme: From baseline to after 12 months
|
Venous blood sampling
|
From baseline to after 12 months
|
|
Plasma glucose after oral glucose tolerance test
Tidsramme: From baseline to after 8 weeks
|
Venous blood sampling 120 minutes after ingesting 75 gram glucose
|
From baseline to after 8 weeks
|
|
Plasma glucose after oral glucose tolerance test
Tidsramme: From baseline to after 12 months
|
Venous blood sampling 120 minutes after ingesting 75 gram glucose
|
From baseline to after 12 months
|
|
Dietary intake
Tidsramme: From baseline to after 8 weeks
|
Self-reported dietary intake using electronic application
|
From baseline to after 8 weeks
|
|
Dietary intake
Tidsramme: From baseline to after 12 months
|
Self-reported dietary intake using electronic application
|
From baseline to after 12 months
|
|
Mean Daily Minutes of Moderate-to-Vigorous Physical Activity Measured by ActiGraph Accelerometer
Tidsramme: From baseline to after 8 weeks
|
Participants will wear an ActiGraph accelerometer for 7 consecutive days. Moderate-to-vigorous physical activity will be determined using prespecified accelerometer count thresholds. For each participant, the total number of minutes classified as moderate-to-vigorous physical activity will be calculated for each valid wear day and averaged across all valid wear days. The reported value will be mean minutes of moderate-to-vigorous physical activity per day. A valid day will be defined as at least 10 hours of accelerometer wear, and participants must have at least 4 valid days to be included in the analysis. |
From baseline to after 8 weeks
|
|
Mean Daily Minutes of Moderate-to-Vigorous Physical Activity Measured by ActiGraph Accelerometer
Tidsramme: From baseline to after 12 months
|
Participants will wear an ActiGraph accelerometer for 7 consecutive days. Moderate-to-vigorous physical activity will be determined using prespecified accelerometer count thresholds. For each participant, the total number of minutes classified as moderate-to-vigorous physical activity will be calculated for each valid wear day and averaged across all valid wear days. The reported value will be mean minutes of moderate-to-vigorous physical activity per day. A valid day will be defined as at least 10 hours of accelerometer wear, and participants must have at least 4 valid days to be included in the analysis. |
From baseline to after 12 months
|
|
Self-reported physical activity
Tidsramme: From baseline to after 8 weeks
|
International Physical Activity Questionnaire
|
From baseline to after 8 weeks
|
|
Self-reported physical activity
Tidsramme: From baseline to after 12 months
|
International Physical Activity Questionnaire
|
From baseline to after 12 months
|
|
Psychological wellbeing
Tidsramme: From baseline to after 8 weeks
|
World Health Organization Five Well-Being Index (WHO-5).
The World Health Organization Five Well-Being Index (WHO-5) is a 5-item self-report questionnaire assessing subjective psychological well-being over the previous 2 weeks.
Raw scores are transformed to a scale ranging from 0 to 100 by multiplying the total raw score by 4. Higher scores indicate better well-being.
|
From baseline to after 8 weeks
|
|
Psychological wellbeing
Tidsramme: From baseline to after 12 months
|
World Health Organization Five Well-Being Index (WHO-5).
The World Health Organization Five Well-Being Index (WHO-5) is a 5-item self-report questionnaire assessing subjective psychological well-being over the previous 2 weeks.
Raw scores are transformed to a scale ranging from 0 to 100 by multiplying the total raw score by 4. Higher scores indicate better well-being.
|
From baseline to after 12 months
|
|
Sleep quality
Tidsramme: From baseline to after 8 weeks
|
Pittsburgh Sleep Quality Index questionnaire global score.
The Pittsburgh Sleep Quality Index (PSQI) is a 19-item self-report questionnaire that assesses sleep quality over the previous month.
The global PSQI score ranges from 0 to 21, with higher scores indicating worse sleep quality.
|
From baseline to after 8 weeks
|
|
Sleep quality
Tidsramme: From baseline to after 12 months
|
Pittsburgh Sleep Quality Index questionnaire global score.
The Pittsburgh Sleep Quality Index (PSQI) is a 19-item self-report questionnaire that assesses sleep quality over the previous month.
The global PSQI score ranges from 0 to 21, with higher scores indicating worse sleep quality.
|
From baseline to after 12 months
|
|
Depression
Tidsramme: From baseline to 8 weeks
|
The Edinburgh Postnatal Depression Scale (EPDS) global score.
The Edinburgh Postnatal Depression Scale is a 10-item self-report questionnaire that assesses symptoms of depression over the previous 7 days.
The total score ranges from 0 to 30, with higher scores indicating more severe depressive symptoms.
|
From baseline to 8 weeks
|
|
Depression
Tidsramme: From baseline to after 12 months
|
The Edinburgh Postnatal Depression Scale (EPDS) global score.
The Edinburgh Postnatal Depression Scale is a 10-item self-report questionnaire that assesses symptoms of depression over the previous 7 days.
The total score ranges from 0 to 30, with higher scores indicating more severe depressive symptoms.
|
From baseline to after 12 months
|
|
Anxiety
Tidsramme: From baseline to after 8 weeks
|
Generalised anxiety disorder questionnaire (GAD-7) total score.
The Generalized Anxiety Disorder 7-Item (GAD-7) is a 7-item self-report questionnaire that assesses symptoms of generalized anxiety over the previous 2 weeks.
The total score ranges from 0 to 21, with higher scores indicating more severe anxiety symptoms.
|
From baseline to after 8 weeks
|
|
Anxiety
Tidsramme: From baseline to after 12 months
|
Generalised anxiety disorder questionnaire (GAD-7) total score.
The Generalized Anxiety Disorder 7-Item (GAD-7) is a 7-item self-report questionnaire that assesses symptoms of generalized anxiety over the previous 2 weeks.
The total score ranges from 0 to 21, with higher scores indicating more severe anxiety symptoms.
|
From baseline to after 12 months
|
|
Type 2 diabetes mellitus diagnosis
Tidsramme: During the 12-month follow-up
|
Participant-reported or measurement of HbA1c of 48 mmol/mol or above
|
During the 12-month follow-up
|
|
Mean Daily Step Count Measured by ActiGraph Accelerometer
Tidsramme: From baseline to after 8 weeks
|
Participants will wear an ActiGraph accelerometer for 7 consecutive days.
The number of steps recorded on each valid wear day will be averaged across all valid wear days for each participant.
A valid day will be defined as at least 10 hours of accelerometer wear, and at least 4 valid days will be required.
|
From baseline to after 8 weeks
|
|
Mean Daily Sedentary Time Measured by ActiGraph Accelerometer
Tidsramme: At baseline and after 8 weeks
|
Participants will wear an ActiGraph accelerometer for 7 consecutive days.
Sedentary time will be identified using a prespecified accelerometer count threshold.
Minutes classified as sedentary will be calculated for each valid wear day and averaged across all valid wear days for each participant.
A valid day will be defined as at least 10 hours of accelerometer wear, and at least 4 valid days will be required.
|
At baseline and after 8 weeks
|
|
Mean Daily Step Count Measured by ActiGraph Accelerometer
Tidsramme: From baseline to after 12 months
|
Participants will wear an ActiGraph accelerometer for 7 consecutive days.
The number of steps recorded on each valid wear day will be averaged across all valid wear days for each participant.
A valid day will be defined as at least 10 hours of accelerometer wear, and at least 4 valid days will be required.
|
From baseline to after 12 months
|
|
Mean Daily Sedentary Time Measured by ActiGraph Accelerometer
Tidsramme: From baseline to after 12 months
|
Participants will wear an ActiGraph accelerometer for 7 consecutive days.
Sedentary time will be identified using a prespecified accelerometer count threshold.
Minutes classified as sedentary will be calculated for each valid wear day and averaged across all valid wear days for each participant.
A valid day will be defined as at least 10 hours of accelerometer wear, and at least 4 valid days will be required.
|
From baseline to after 12 months
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Infant feeding method
Tidsramme: Baseline, 8 weeks, and after 12 months
|
Infant feeding practices will be assessed using a study questionnaire.
Feeding method will be categorized as exclusive breastfeeding, partial breastfeeding, exclusive formula feeding, or complementary feeding, as appropriate for the infant's age.
The number and proportion of infants in each feeding category will be reported at each assessment.
|
Baseline, 8 weeks, and after 12 months
|
|
Adherence to time-restricted eating
Tidsramme: Baseline, after 8 weeks and after 12 months
|
Time-frame for daily energy intake, reported as average and percentage of participants who adhere to < 10 hours daily energy intake window
|
Baseline, after 8 weeks and after 12 months
|
|
Adherence to exercise training
Tidsramme: During the 8-week intervention and during the 12-month follow-up
|
Number of completed sessions, recorded using an electronic application
|
During the 8-week intervention and during the 12-month follow-up
|
|
Perception of intervention and follow-up
Tidsramme: After 12 months
|
Qualitative interviews with selected participants to explore barriers and motivators
|
After 12 months
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Trine Moholdt, PhD, Norwegian University of Science and Technology
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Anslået)
15. august 2026
Primær færdiggørelse (Anslået)
1. december 2028
Studieafslutning (Anslået)
1. januar 2029
Datoer for studieregistrering
Først indsendt
3. juli 2026
Først indsendt, der opfyldte QC-kriterier
17. august 2026
Først opslået (Faktiske)
20. august 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
20. august 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
17. august 2026
Sidst verificeret
1. august 2026
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 987380
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
JA
IPD-planbeskrivelse
We will make de-identified individual participant data (IPD) collected in the study available to other researchers. We will upload a data set in an open access repository.
We will only share IPD that cannot be used to identify individuals.
IPD-delingstidsramme
Data will become available at the time of publication of the results from the study
IPD-delingsadgangskriterier
De-identified individual participant data underlying published results will be available upon reasonable request following publication of the primary study results.
Requests must be accompanied by a research proposal and statistical analysis plan. Requests will be reviewed by the Principal Investigator and study investigators for scientific merit, feasibility, consistency with participant consent, and compliance with applicable ethical and legal requirements. Approved researchers will be required to sign a data sharing agreement.
Only de-identified data will be shared. Data may be modified as necessary to minimize the risk of participant re-identification while preserving scientific utility.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .